Affimed (NASDAQ:AFMD – Get Free Report) saw a significant drop in short interest in the month of September. As of September 30th, there was short interest totalling 653,600 shares, a drop of 5.8% from the September 15th total of 694,100 shares. Based on an average trading volume of 92,100 shares, the days-to-cover ratio is presently 7.1 days. Currently, 5.0% of the shares of the stock are sold short.
Institutional Investors Weigh In On Affimed
A hedge fund recently bought a new stake in Affimed stock. Choreo LLC acquired a new stake in shares of Affimed (NASDAQ:AFMD – Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 10,000 shares of the biopharmaceutical company’s stock, valued at approximately $54,000. Choreo LLC owned about 0.07% of Affimed at the end of the most recent quarter. 30.82% of the stock is owned by hedge funds and other institutional investors.
Affimed Price Performance
AFMD stock opened at $3.13 on Wednesday. The company’s 50 day moving average is $3.79 and its 200 day moving average is $4.88. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.71 and a current ratio of 2.71. Affimed has a 1-year low of $2.23 and a 1-year high of $8.95.
Analyst Ratings Changes
AFMD has been the topic of a number of analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Affimed in a report on Monday, September 9th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Affimed in a report on Friday, September 6th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Affimed currently has a consensus rating of “Moderate Buy” and an average price target of $20.00.
Get Our Latest Stock Report on AFMD
Affimed Company Profile
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.
Further Reading
- Five stocks we like better than Affimed
- Top Stocks Investing in 5G Technology
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- What does consumer price index measure?
- AMD Gains Momentum With AI: Can It Beat Expectations?
- What Does a Stock Split Mean?
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.